Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Next Previous
Trial Profile

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary)
  • Indications Pemphigoid; Stevens-Johnson syndrome; Toxic epidermal necrolysis
  • Focus Adverse reactions

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment as No patients met eligibility criteria.
    • 03 Apr 2017 Planned End Date changed from 1 Mar 2017 to 3 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top